Company Registration No. 01159518 (England and Wales)
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
COMPANY INFORMATION
Directors
Mr R Biskupek
Mr S Hall
(Appointed 18 July 2025)
Company number
01159518
Registered office
7 & 8 Launton Business Centre
Murdock Road
Bicester
Oxon
OX26 4XB
Auditor
Shaw Gibbs (Audit) Limited
264 Banbury Road
Oxford
England
OX2 7DY
Bankers
Handelsbanken (Oxford Parkway)
Oxford Parkway Branch
Latimer House
Langford Business Park
Kidlington
OX5 1GG
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
CONTENTS
Page
Strategic report
1
Directors' report
2 - 3
Independent auditor's report
4 - 6
Profit and loss account
7
Balance sheet
8
Statement of changes in equity
9
Statement of cash flows
10
Notes to the financial statements
11 - 23
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The directors present the strategic report for the year ended 31 December 2025.

Review of the business

The Company’s reporting period now aligns with the Group reporting structure, with a year end of 31 December. The comparative period therefore reflects a shortened 10-month period ended 31 December 2024.

The Directors report revenue of £10.446 million for the year ended 31 December 2025 (10 months to 31 December 2024: £8.320 million). The increase reflects continued growth in the business, however, the Directors note that the prior period covered only ten months and is therefore not directly comparable.

Profit before tax for the year ended 31 December 2025 was £1.789 million (10 months to 31 December 2024: £0.888 million). The improvement in profitability reflects increased revenue and continued operational efficiencies, noting the shortened comparative period.

Debtors as at 31 December 2025 were £6.349 million (31 December 2024: £4.647 million). The increase primarily relates to short-term loans extended to Group companies.

Principal risks and uncertainties

The Directors remain confident in the long-term growth prospects of the business. However, they continue to monitor developments in rapid detection technologies, which may impact certain areas of the market.

The business also operates against a backdrop of ongoing geopolitical uncertainty, including developments in Ukraine, the Middle East, and wider global economic conditions. These factors may influence customer demand, supply chain stability, and cost inflation.

Maintaining a resilient and flexible supply chain remains a key priority for 2026 and beyond.

Key performance indicators

The Directors assess the performance of the business primarily through revenue and profit growth. In addition, the Company monitors a range of operational and quality-related key performance indicators to ensure continued delivery of high standards and efficiency.

Future Development

The Company continues to mitigate risks associated with the development of rapid detection technologies through its strategic partnership with a specialist provider and its UK distribution agreement.

As part of the AnalytiChem Group, the business continues to benefit from cross-selling opportunities and enhanced market access These advantages are expected to support further growth and development.

On behalf of the board

Mr S Hall
Director
2 April 2026
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

Principal activities

The principal activities of the company during the year were the manufacture and supply of ready prepared microbiological media; the manufacture, distribution, repair and servicing of cleanroom monitoring equipment and accessories.

Results and dividends

The results for the year are set out on page 7.

No ordinary dividends were paid. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr A R Whittard
(Resigned 29 August 2025)
Mr R Biskupek
Mr S Hall
(Appointed 18 July 2025)
Auditor

The auditor, Shaw Gibbs (Audit) Limited, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Strategic report

The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
Statement of disclosure to auditor

So far as the directors are aware, there is no relevant audit information of which the company's auditor are unaware. Additionally, the directors have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company's auditors are aware of that information.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
Mr S Hall
Director
2 April 2026
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
- 4 -
Opinion

We have audited the financial statements of Analytichem UK Ltd (formerly known as Cherwell Laboratories Limited) (the 'company') for the year ended 31 December 2025 which comprise the profit and loss account, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED) (CONTINUED)
- 5 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

 

  1. At the planning stage of the audit we gain an understanding of the laws and regulations which apply to the company and how the management seek to comply with those laws regulations. This helps us to plan appropriate risk assessments.

  2. During the audit we focused on relevant risk areas and review the compliance with the laws and regulations by making relevant enquiries and undertaking corroboration, for example by reviewing Board Minutes and other documentation.

     

  3. We assessed the risk of material misstatement in the financial statements including as a result of fraud and undertook procedures including:

    1. Reviewing the controls set in place by management

    2. Making enquiries of management as to whether they consider fraud or other irregularity may have taken place, or where such opportunity might exist

    3. Challenging management assumptions with regard to accounting estimates

    4. Identifying and testing journal entries, particularly those which appear to be unusual by size or nature

    5. Reviewing health and safety reports and obtaining BSI audit results to ensure that the company has complied with the appropriate requirements.

 

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED) (CONTINUED)
- 6 -

Because of the inherent limitations of an audit, there is a risk that we will not detect all regularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Stephen Howard Neal (Senior Statutory Auditor)
For and on behalf of Shaw Gibbs (Audit) Limited, Statutory Auditor
Chartered Certified Accountants
264 Banbury Road
Oxford
OX2 7DY
England
2 April 2026
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
Year ended December 2025
Period ended December 2024
Notes
£
£
Turnover
3
10,446,051
8,320,878
Cost of sales
(5,478,397)
(4,404,012)
Gross profit
4,967,654
3,916,866
Administrative expenses
(3,455,580)
(3,208,821)
Operating profit
4
1,512,074
708,045
Interest receivable and similar income
8
276,893
179,750
Profit before taxation
1,788,967
887,795
Tax on profit
9
(304,013)
(84,649)
Profit for the financial year
1,484,954
803,146

The profit and loss account has been prepared on the basis that all operations are continuing operations.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 8 -
Year ended December 2025
Period ended December 2024
Notes
£
£
£
£
Fixed assets
Tangible assets
10
1,232,131
1,034,249
Current assets
Stocks
11
782,615
674,128
Debtors
12
6,349,400
4,647,151
Cash at bank and in hand
466,919
576,330
7,598,934
5,897,609
Creditors: amounts falling due within one year
13
(1,771,039)
(1,356,786)
Net current assets
5,827,895
4,540,823
Total assets less current liabilities
7,060,026
5,575,072
Provisions for liabilities
Provisions
14
609,844
609,844
Deferred tax liability
15
240,000
240,000
(849,844)
(849,844)
Net assets
6,210,182
4,725,228
Capital and reserves
Called up share capital
17
4,125
4,125
Share premium account
27,875
27,875
Profit and loss reserves
6,178,182
4,693,228
Total equity
6,210,182
4,725,228

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 2 April 2026 and are signed on its behalf by:
Mr S  Hall
Director
Company registration number 01159518 (England and Wales)
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
Share capital
Share premium account
Profit and loss reserves
Total
£
£
£
£
Balance at 1 March 2024
4,125
27,875
3,890,082
3,922,082
Period ended 31 December 2024:
Profit and total comprehensive income
-
-
803,146
803,146
Balance at 31 December 2024
4,125
27,875
4,693,228
4,725,228
Year ended 31 December 2025:
Profit and total comprehensive income
-
-
1,484,954
1,484,954
Balance at 31 December 2025
4,125
27,875
6,178,182
6,210,182
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
31 December 2025
31 December 2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
22
1,864,290
1,427,065
Income taxes paid
(19,692)
(71)
Net cash inflow from operating activities
1,844,598
1,426,994
Investing activities
Purchase of tangible fixed assets
(428,178)
(394,179)
Loans made to group undertakings
(1,802,724)
(2,697,051)
Interest received
276,893
179,750
Net cash used in investing activities
(1,954,009)
(2,911,480)
Net decrease in cash and cash equivalents
(109,411)
(1,484,486)
Cash and cash equivalents at beginning of year
576,330
2,060,816
Cash and cash equivalents at end of year
466,919
576,330
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
1
Accounting policies
Company information

Analytichem UK Ltd (formerly known as Cherwell Laboratories Limited) is a private company limited by shares incorporated in England and Wales. The registered office is 7 & 8 Launton Business Centre, Murdock Road, Bicester, Oxon, OX26 4XB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared on the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Reporting period

The accounting reference date of the company was changed last year from 28 February to 31 December, to align with other group companies. The comparative period covers the 10 month period ended 31 December 2024. Therefore the figures presented in these financial statements will not be entirely comparable.

1.4
Turnover

The turnover shown in the profit and loss account represents amounts invoiced during the year, exclusive of Value Added Tax.

 

Income is recognised when goods are dispatched from the warehouse or at the point repair and service of equipment is completed.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Cleanroom
10% straight line
Leasehold improvements
10% straight line
Engineering & warehouse equipment
10% to 20% straight line
Office fixtures & equipment
10% to 33% straight line
Production equipment
10% to 20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 12 -
1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs incurred in bringing the stocks to their present location and condition. Stock is valued using the FIFO method.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 13 -
Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 14 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11
Provisions

Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

 

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

Where material, the cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 15 -
1.15
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Useful economic life of non-current assets

The useful economic lives of non-current assets have been derived from the judgement of the directors, using their best estimate of the write-down period.

Dilapidations provision

The dilapidations provision with respect to the premises rented by the company is based on a professional dilapidations assessment that was carried out by a firm of Chartered Surveyors. The directors have used the professional assessment as a basis for estimating the value of the dilapidations provision and they have also applied their commercial judgement (by considering a number of variables such as the subsequent alterations made in the properties, the changes in the economy and the commercial properties market etc) to assess the need to revise upwards the relevant provision. The adequacy of the dilapidations provision and the necessity for an additional professional assessment is monitored by the directors on an annual basis. Adjustments are made as and when necessary to ensure the adequacy of the relevant provision.

Stock valuation and obsolescence

Stocks are valued at the lower of cost and estimated selling price less costs to complete and sell. Costs comprise direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Stock is valued using the FIFO method.

 

Estimated selling price less costs to complete and sell, includes, where necessary, provisions for slow moving and obsolete stocks. Calculation of these provisions requires estimates to be made, which include the forecasted customer demand, the promotional, competitive and economic environment as well as the ageing of stock and the discontinuation of certain product lines by the key suppliers. These variables are monitored by the directors and a provision is put in place where deemed reasonable to mitigate the relevant risks.

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 16 -
3
Turnover and other revenue

An analysis of the company's turnover is as follows:

Year ended December 2025
Period ended December 2024
£
£
Turnover analysed by geographical market
United Kingdom
9,230,415
7,229,013
Europe
1,001,051
1,006,800
Rest of World
214,585
85,065
10,446,051
8,320,878
Year ended December 2025
Period ended December 2024
£
£
Other revenue
Interest income
276,893
179,750
4
Operating profit
Year ended December 2025
Period ended December 2024
Operating profit for the year is stated after charging:
£
£
Exchange losses
634
1,860
Depreciation of tangible fixed assets
230,296
172,171
(Profit)/loss on disposal of tangible fixed assets
-
183,414
Operating lease charges
298,491
388,511
5
Auditor's remuneration
Year ended December 2025
Period ended December 2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the company
15,500
13,900
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 17 -
6
Directors' remuneration
Year ended December 2025
Period ended December 2024
£
£
Remuneration for qualifying services
79,483
52,912
Company pension contributions to defined contribution schemes
57,285
48,361
136,768
101,273
7
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

Year ended December 2025
Period ended December 2024
Number
Number
Directors
2
2
Administration
19
21
Production
67
67
Total
88
90

Their aggregate remuneration comprised:

Year ended December 2025
Period ended December 2024
£
£
Wages and salaries
3,417,177
2,850,572
Social security costs
131,419
106,673
Pension costs
95,343
81,621
3,643,939
3,038,866
8
Interest receivable and similar income
Year ended December 2025
Period ended December 2024
£
£
Interest income
Interest on bank deposits
16,625
20,640
Other interest income
260,268
159,110
Total income
276,893
179,750
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 18 -
9
Taxation
Year ended December 2025
Period ended December 2024
£
£
Current tax
UK corporation tax on profits for the current period
304,013
19,760
Adjustments in respect of prior periods
-
0
52,881
Total current tax
304,013
72,641
Deferred tax
Origination and reversal of timing differences
-
0
12,008
Total tax charge
304,013
84,649

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

Year ended December 2025
Period ended December 2024
£
£
Profit before taxation
1,788,967
887,795
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (Period ended December 2024: 25.00%)
447,242
221,949
Tax effect of expenses that are not deductible in determining taxable profit
3,849
50,866
Tax effect of utilisation of tax losses not previously recognised
-
0
(115,996)
Group relief
(90,534)
(76,726)
Under/(over) provided in prior years
-
0
52,881
(Accelerated)/decelerated capital allowances
(31,485)
(60,333)
Deferred tax current year
-
0
12,008
Taxation charge for the year
329,072
84,649
Taxation charge in the financial statements
304,013
84,649
Reconciliation - the current year tax charge does not reconcile to the above analysis.  Please review figures in the database.
25,059
-
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 19 -
10
Tangible fixed assets
Cleanroom
Leasehold improvements
Production equipment
Office fixtures & equipment
Engineering & warehouse equipment
Total
£
£
£
£
£
£
Cost
At 1 January 2025
1,823,762
425,923
855,005
785,308
229,707
4,119,705
Additions
207,810
18,922
59,753
133,001
8,692
428,178
At 31 December 2025
2,031,572
444,845
914,758
918,309
238,399
4,547,883
Depreciation and impairment
At 1 January 2025
1,479,864
229,234
667,646
514,038
194,674
3,085,456
Depreciation charged in the year
50,696
42,625
67,022
60,355
9,598
230,296
At 31 December 2025
1,530,560
271,859
734,668
574,393
204,272
3,315,752
Carrying amount
At 31 December 2025
501,012
172,986
180,090
343,916
34,127
1,232,131
At 31 December 2024
343,898
196,689
187,359
271,270
35,033
1,034,249

 

11
Stocks
Year ended December 2025
Period ended December 2024
£
£
Raw materials and consumables
481,798
367,081
Work in progress
216
6,368
Finished goods and goods for resale
300,601
300,679
782,615
674,128
12
Debtors
Year ended December 2025
Period ended December 2024
Amounts falling due within one year:
£
£
Trade debtors
1,322,682
1,248,965
Amounts owed by group undertakings
4,834,620
3,032,766
Prepayments and accrued income
192,098
365,420
6,349,400
4,647,151
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 20 -
13
Creditors: amounts falling due within one year
Year ended December 2025
Period ended December 2024
£
£
Trade creditors
626,970
630,858
Amounts owed to group undertakings
292,619
140,492
Corporation tax
304,010
19,689
Other taxation and social security
378,652
425,585
Other creditors
20,000
18,489
Accruals and deferred income
148,788
121,673
1,771,039
1,356,786
14
Provisions for liabilities
Year ended December 2025
Period ended December 2024
£
£
Provision
609,844
609,844
Movements on provisions:
Provision
£
At 1 January 2025 and 31 December 2025
609,844

The balance of provisions relates to property dilapidations of £609,844 (2024: £609,844) based on the cost estimated by an independent survey.

15
Deferred taxation

Deferred tax assets and liabilities are offset where the company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:

Liabilities
Liabilities
Year ended December 2025
Period ended December 2024
Balances:
£
£
Accelerated capital allowances
240,000
240,000
There were no deferred tax movements in the year.
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
16
Retirement benefit schemes
Year ended December 2025
Period ended December 2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
95,343
81,621

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

 

At the year end date, amounts payable to the pension scheme totaled £20,000 (2024: £18,489).

17
Share capital
Year ended December 2025
Period ended December 2024
Year ended December 2025
Period ended December 2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of 50p each
8,000
8,000
4,000
4,000
Ordinary B shares of 50p each
250
250
125
125
8,250
8,250
4,125
4,125

 

18
Financial commitments, guarantees and contingent liabilities

Kroll Trustee Services Limited holds security by way of fixed and floating charge covering all property and/or undertakings of the company. This was created on 15 February 2024.

 

This charge is in relation to an €88,000,0000 loan facility taken out by the ultimate parent company.

19
Capital commitments

Amounts contracted for but not provided in the financial statements:

Year ended December 2025
Period ended December 2024
£
£
Acquisition of tangible fixed assets
-
160,808
20
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
20
Operating lease commitments
(Continued)
- 22 -
Year ended December 2025
Period ended December 2024
£
£
Amount payable within one year
425,733
281,640
Between two and five years
1,656,388
5,809
In over five years
4,100,000
-
0
6,182,121
287,449
21
Related party transactions

The company has taken advantage of of the exemptions provided by Section 33 of FRS 102 not to disclose transactions and outstanding balances with other wholly owned members of the group headed by AnalytiChem Investment GmbH.

22
Cash generated from operations
Year ended December 2025
Period ended December 2024
£
£
Profit after taxation
1,484,954
803,146
Adjustments for:
Taxation charged
304,013
84,649
Investment income
(276,893)
(179,750)
(Gain)/loss on disposal of tangible fixed assets
-
183,414
Depreciation and impairment of tangible fixed assets
230,296
172,171
Movements in working capital:
(Increase)/decrease in stocks
(108,487)
13,065
Decrease in debtors
100,475
83,832
Increase in creditors
129,932
266,538
Cash generated from operations
1,864,290
1,427,065
23
Analysis of changes in net funds
1 January 2025
Cash flows
31 December 2025
£
£
£
Cash at bank and in hand
576,330
(109,411)
466,919
ANALYTICHEM UK LTD (FORMERLY KNOWN AS CHERWELL LABORATORIES LIMITED)
NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 23 -
24
Ultimate controlling party

The immediate parent company is AnalytiChem Holding (UK) Limited, a company registered in England and Wales with a registered office, 7 & 8 Launton Business Centre Murdock Road, Murdock Road, Bicester, England, OX26 4XB.

The ultimate parent company is AnalytiChem Investment GmbH, a company incorporated in Germany with a registered office of Frankfurter Str. 80-82, 65760 Eschborn, Germany.

2025-12-312025-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2026.200Mr A R WhittardMr R BiskupekMr S Hall011595182025-01-012025-12-3101159518bus:Director22025-01-012025-12-3101159518bus:Director32025-01-012025-12-3101159518bus:Director12025-01-012025-12-3101159518bus:RegisteredOffice2025-01-012025-12-3101159518bus:Agent12025-01-012025-12-31011595182025-12-31011595182024-03-012024-12-3101159518core:RetainedEarningsAccumulatedLosses2024-03-012024-12-3101159518core:RetainedEarningsAccumulatedLosses2025-01-012025-12-31011595182024-12-3101159518core:LandBuildingscore:OwnedOrFreeholdAssets2025-12-3101159518core:LandBuildings2025-12-3101159518core:PlantMachinery2025-12-3101159518core:FurnitureFittings2025-12-3101159518core:ComputerEquipment2025-12-3101159518core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-3101159518core:LandBuildings2024-12-3101159518core:PlantMachinery2024-12-3101159518core:FurnitureFittings2024-12-3101159518core:ComputerEquipment2024-12-3101159518core:WithinOneYear2025-12-3101159518core:WithinOneYear2024-12-3101159518core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3101159518core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3101159518core:ShareCapital2025-12-3101159518core:ShareCapital2024-12-3101159518core:SharePremium2025-12-3101159518core:SharePremium2024-12-3101159518core:RetainedEarningsAccumulatedLosses2025-12-3101159518core:RetainedEarningsAccumulatedLosses2024-12-3101159518core:ShareCapital2024-02-2901159518core:SharePremium2024-02-2901159518core:RetainedEarningsAccumulatedLosses2024-02-2901159518core:ShareCapitalOrdinaryShareClass12025-12-3101159518core:ShareCapitalOrdinaryShareClass12024-12-3101159518core:ShareCapitalOrdinaryShareClass22025-12-3101159518core:ShareCapitalOrdinaryShareClass22024-12-3101159518core:ShareCapitalOrdinaryShares2025-12-3101159518core:ShareCapitalOrdinaryShares2024-12-31011595182024-12-31011595182024-02-2901159518core:LandBuildingscore:OwnedOrFreeholdAssets2025-01-012025-12-3101159518core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-01-012025-12-3101159518core:PlantMachinery2025-01-012025-12-3101159518core:FurnitureFittings2025-01-012025-12-3101159518core:ComputerEquipment2025-01-012025-12-3101159518core:UKTax2025-01-012025-12-3101159518core:UKTax2024-03-012024-12-310115951812025-01-012025-12-310115951812024-03-012024-12-310115951822025-01-012025-12-310115951822024-03-012024-12-310115951832025-01-012025-12-310115951832024-03-012024-12-3101159518core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-3101159518core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3101159518core:PlantMachinery2024-12-3101159518core:FurnitureFittings2024-12-3101159518core:ComputerEquipment2024-12-3101159518core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-12-3101159518core:CurrentFinancialInstruments2025-12-3101159518core:CurrentFinancialInstruments2024-12-3101159518bus:OrdinaryShareClass12025-01-012025-12-3101159518bus:OrdinaryShareClass22025-01-012025-12-3101159518bus:OrdinaryShareClass12025-12-3101159518bus:OrdinaryShareClass12024-12-3101159518bus:OrdinaryShareClass22025-12-3101159518bus:OrdinaryShareClass22024-12-3101159518bus:AllOrdinaryShares2025-12-3101159518bus:AllOrdinaryShares2024-12-3101159518core:BetweenTwoFiveYears2025-12-3101159518core:BetweenTwoFiveYears2024-12-3101159518core:MoreThanFiveYears2025-12-3101159518core:MoreThanFiveYears2024-12-3101159518bus:PrivateLimitedCompanyLtd2025-01-012025-12-3101159518bus:FRS1022025-01-012025-12-3101159518bus:Audited2025-01-012025-12-3101159518bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP